Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $287.00 at Wells Fargo & Company

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price objective hoisted by stock analysts at Wells Fargo & Company from $275.00 to $287.00 in a report issued on Friday,Benzinga reports. The firm currently has an "equal weight" rating on the biopharmaceutical company's stock. Wells Fargo & Company's target price would suggest a potential upside of 2.15% from the stock's previous close.

A number of other research firms have also recently commented on ALNY. JPMorgan Chase & Co. boosted their price objective on Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a "neutral" rating in a research report on Tuesday, March 11th. StockNews.com lowered shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday. HC Wainwright upped their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a "buy" rating in a research report on Monday, February 24th. Chardan Capital reiterated a "buy" rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday. Finally, William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $312.30.

Remove Ads

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded down $9.74 during midday trading on Friday, hitting $280.96. 1,065,379 shares of the stock traded hands, compared to its average volume of 806,039. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock's fifty day simple moving average is $258.62 and its 200-day simple moving average is $260.26. The firm has a market cap of $36.37 billion, a P/E ratio of -129.47 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insiders Place Their Bets

In related news, CMO Pushkal Garg sold 52,592 shares of the firm's stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. The trade was a 10.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,234 shares of company stock valued at $19,958,097 over the last ninety days. Company insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ALNY. California State Teachers Retirement System lifted its holdings in shares of Alnylam Pharmaceuticals by 2.6% in the 4th quarter. California State Teachers Retirement System now owns 196,362 shares of the biopharmaceutical company's stock worth $46,206,000 after acquiring an additional 5,037 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Alnylam Pharmaceuticals by 94.7% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 12,566 shares of the biopharmaceutical company's stock valued at $2,957,000 after purchasing an additional 6,112 shares during the period. Lansforsakringar Fondforvaltning AB publ acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $10,011,000. Bannerman Wealth Management Group LLC purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $327,000. Finally, Siemens Fonds Invest GmbH grew its stake in shares of Alnylam Pharmaceuticals by 137.7% in the fourth quarter. Siemens Fonds Invest GmbH now owns 3,245 shares of the biopharmaceutical company's stock valued at $764,000 after buying an additional 1,880 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.